Source comparison
Tesamorelin Oral vs Injectable: Comparison Table
The table below compares the key differentiators between tesamorelin oral vs injectable administration routes across bioavailability, clinical validation, cost-efficiency, and practical handling. Bioavailability Approaches 100%. Peptide bypasses digestive enzy
This comparison does not assign a generated winner or score.
- The table below compares the key differentiators between tesamorelin oral vs injectable administration routes across bioavailability, clinical validation, cost-efficiency, and practical handling.
- Bioavailability
- Approaches 100%. Peptide bypasses digestive enzymes and enters systemic circulation intact via subcutaneous absorption
- Estimated <1% without advanced delivery technology; gastric acid and proteolytic enzymes degrade the peptide before intestinal absorption
- Injectable is the only route with clinically meaningful bioavailability
- Clinical Evidence
- Supported by Phase 3 randomised controlled trials showing 15–18% VAT reduction at 26 weeks (published NEJM, Lancet)
- No peer-reviewed clinical trials; no FDA-approved oral tesamorelin product exists as of 2026
- Injectable is the only evidence-based option
- Cost per Effective Dose
- 2mg vial costs approximately $80–$150; one vial = one full 2mg dose with near-complete absorption
- Even at 12% bioavailability (optimistic), would require 10× the dose to match injectable plasma levels. Cost becomes prohibitive
- Injectable delivers better cost-efficiency per bioavailable milligram
- Storage Stability
- Lyophilised powder stable 24 months refrigerated; reconstituted solution stable 28 days at 2–8°C; visual inspection confirms integrity
- Oral capsules claim room-temperature stability but lack cold-chain verification; potency degradation invisible to the user
- Injectable offers verifiable stability and longer shelf life
- Adverse Events
- Injection site reactions (20–30%), arthralgia, peripheral edema; monitored in clinical trials with established safety profile
- Speculative. No clinical safety data; permeation enhancers may cause GI irritation; systemic risks unknown
- Injectable has a known, documented safety profile
- Ease of Use
- Requires reconstitution, syringe preparation, subcutaneous injection; 60-second procedure after initial learning curve
- Oral administration requires no injection; convenient but ineffective without specialized encapsulation
- Convenience is irrelevant if the product doesn't work